Salix Pharmaceuticals, Ltd. Release: FDA Approves RELISTOR Subcutaneous Injection For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- --Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals, Inc. today announced that the Food and Drug Administration has approved RELISTORA Subcutaneous Injection, 12 mg/0.6ml, for the treatment of opioid-induced constipation in patients taking opioids for chronic non-cancer pain. RELISTOR subcutaneous injection is currently the only available peripherally acting mu opioid receptor antagonist that is approved for treating OIC at the cause without interfering with the centrally acting analgesic properties of the opioid.
http://ift.tt/1tec38d
http://ift.tt/1tec38d
No comments:
Post a Comment